PDCD1 and colorectal carcinoma: Although CIMP-H tumors are conceptually expected to be more responsive to anti-PD-1/PD-L1 immunotherapy than CIMP-L/0 tumors, our MSI-H CRC cohort was retrospectively collected, and only a few patients received immunotherapy using ICB.